160 likes | 389 Views
THE NEW IWGDF GUIDELINES. Nicolaas Schaper. www.iwgdfguidelines.org. Slides courtesy IWGDF; available at: www.iwgdfguidelines.org. Plus: Definitions and criteria 10 systematic reviews. >100 experts from >40 countries.
E N D
THE NEW IWGDF GUIDELINES Nicolaas Schaper www.iwgdfguidelines.org
Slides courtesy IWGDF; available at: www.iwgdfguidelines.org Plus: • Definitionsand criteria • 10 systematic reviews >100 experts from >40 countries
Slides courtesy IWGDF; available at: www.iwgdfguidelines.org IWGDF Sponsors Platinum sponsor: Gold sponsors: Silver sponsors: Bronze sponsors:
Sicco Bus Jaap van Netten Jan Apelqvist Robert Hinchliffe Benjamin Lipsky Nicolaas Schaper www.iwgdfguidelines.org
Slides courtesy IWGDF; available at: www.iwgdfguidelines.org Conflict of interest statement • Production of the 2019 IWGDF Guidelines was supported by unrestricted grants from the following sponsors: Molnlycke Healthcare, Acelity, ConvaTec, Urgo Medical, Edixomed, Klaveness, Reapplix, Podartis, Aurealis, SoftOx, Woundcare Circle, and Essity. • All individual conflict of interest statement of authors of this guideline can be found at: https://iwgdfguidelines.org/about-iwgdf-guidelines/biographies/ • Authors were not involved in discussions related to papers they co-authored
Slides courtesy IWGDF; available at: www.iwgdfguidelines.org Malvern, 1996 Amsterdam, 1997
Slides courtesy IWGDF; available at: www.iwgdfguidelines.org 1999 2003 2007 2015 2011
Slides courtesy IWGDF; available at: www.iwgdfguidelines.org Editorial board: 6 members Six workinggroups: 49 members External experts: 50 experts, from 40 countries, from 5 continents
Slides courtesy IWGDF; available at: www.iwgdfguidelines.org GRADE methodology Guyatt et al, 2008; Alonso-Coelo et al, 2016
Slides courtesy IWGDF; available at: www.iwgdfguidelines.org 1: Formulateclinicalquestions • PICO format • Patient • Intervention • (Comparison) • Outcome • The question youaskdeterminestheansweryou get • Reviewedbyexternal experts and editorial board
Slides courtesy IWGDF; available at: www.iwgdfguidelines.org 2: Outcomemeasures • Define: • Critically important outcomes • Important, but notcritical, outcomes • Not important outcomes • Critically important: e.g. ulcerincidence, ulcerhealing, amputation
Slides courtesy IWGDF; available at: www.iwgdfguidelines.org 3. Systematic review • Systematic reviews of theliteratureaccordingto PRISMA • 10 systematic reviews
Slides courtesy IWGDF; available at: www.iwgdfguidelines.org 4. Formulaterecommendations • Strength of recommendation (strong – weak) • Quality of evidence • Balance between benefits andharms • Patientvaluesandpreferences • Resource utilization • Quality of Evidence (high – moderate – low) • Risk of bias of included studies • Effect size • Expert opinion • Inconsistency, indirectness or imprecisionnot taken into account
Slides courtesy IWGDF; available at: www.iwgdfguidelines.org 4. Formulaterecommendations In a person with diabetes and a foot ulcer, use the SINBAD system for communication among health professionals about the characteristics of the ulcer (Strong; Moderate)
Slides courtesy IWGDF; available at: www.iwgdfguidelines.org 10 yearsfull-timework 2 millionEuros in in-kind contributions
Slides courtesy IWGDF; available at: www.iwgdfguidelines.org www.iwgdfguidelines.org